| Primary |
| Glioblastoma Multiforme |
52.4% |
| Glioblastoma |
10.6% |
| Malignant Glioma |
9.8% |
| Drug Use For Unknown Indication |
4.8% |
| Prophylaxis |
3.6% |
| Brain Cancer Metastatic |
2.5% |
| Astrocytoma Malignant |
2.0% |
| Brain Neoplasm |
1.7% |
| Glioma |
1.7% |
| Gliosarcoma |
1.7% |
| Metastases To Central Nervous System |
1.4% |
| Anaplastic Ependymoma |
1.1% |
| Constipation Prophylaxis |
1.1% |
| Hypertension |
1.1% |
| Inflammation |
1.1% |
| Product Used For Unknown Indication |
1.1% |
| Anaplastic Astrocytoma |
0.6% |
| Astrocytoma |
0.6% |
| Metastases To Spine |
0.6% |
| Oligodendroglioma |
0.6% |
|
| Pulmonary Embolism |
12.8% |
| Vomiting |
9.2% |
| Thrombocytopenia |
8.3% |
| Wound Infection |
6.4% |
| Staphylococcal Infection |
5.5% |
| Non-small Cell Lung Cancer |
4.6% |
| Postoperative Wound Infection |
4.6% |
| Pyrexia |
4.6% |
| Urinary Tract Infection |
4.6% |
| Convulsion |
3.7% |
| Disease Progression |
3.7% |
| Haematoma |
3.7% |
| Headache |
3.7% |
| Incision Site Infection |
3.7% |
| Mental Status Changes |
3.7% |
| Osteitis |
3.7% |
| Pneumocephalus |
3.7% |
| Sepsis |
3.7% |
| Visual Acuity Reduced |
3.7% |
| Brain Abscess |
2.8% |
|
| Secondary |
| Glioblastoma Multiforme |
48.0% |
| Glioblastoma |
22.0% |
| Ependymoma |
14.0% |
| Glioma |
8.0% |
| Ill-defined Disorder |
2.0% |
| Mood Altered |
2.0% |
| Product Used For Unknown Indication |
2.0% |
| Pulmonary Embolism |
2.0% |
|
| Hydrocephalus |
9.1% |
| No Therapeutic Response |
9.1% |
| Pulmonary Embolism |
9.1% |
| Thyroid Cyst |
9.1% |
| Confusional State |
4.5% |
| Deep Vein Thrombosis |
4.5% |
| General Physical Condition Abnormal |
4.5% |
| Hiatus Hernia |
4.5% |
| Mental Status Changes |
4.5% |
| Nervous System Disorder |
4.5% |
| Paraesthesia |
4.5% |
| Pneumonia Aspiration |
4.5% |
| Procedural Complication |
4.5% |
| Renal Impairment |
4.5% |
| Urinary Tract Infection Bacterial |
4.5% |
| Visual Acuity Reduced |
4.5% |
| White Blood Cell Count Increased |
4.5% |
| Wound Infection |
4.5% |
|
| Concomitant |
| Glioblastoma |
31.3% |
| Glioblastoma Multiforme |
25.0% |
| Prophylaxis |
25.0% |
| Malignant Glioma |
12.5% |
| Convulsion Prophylaxis |
6.3% |
|
| Neuropathy |
33.3% |
| Cardio-respiratory Arrest |
11.1% |
| Hepatotoxicity |
11.1% |
| Partial Seizures |
11.1% |
| Pulmonary Embolism |
11.1% |
| Rash |
11.1% |
| Visual Acuity Reduced |
11.1% |
|
